Pfizer Reports Phase 3 extension Data for Resmetirom in Myelodysplastic syndrome

Pfizer today announced Phase 3 extension results for Resmetirom in patients with Myelodysplastic syndrome. The study demonstrated that Resmetirom reduces exacerbation rates significantly compared to standard of care or placebo. These results provide important insights into the treatment of Myelodysplastic syndrome and support the continued development of Resmetirom in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Resmetirom was consistent with previous observations, with no new safety signals identified.